Moderna (MRNA) operating cash flow was -$1.9B in FY2025 (+38% YoY). The tables below show the complete quarterly and annual operating cash flow history, sourced from SEC EDGAR 10-K and 10-Q filings.
Annual Operating Cash Flow
Fiscal Year
Operating Cash Flow
YoY
2025
-$1.9B
+38%
2024
-$3.0B
+4%
2023
-$3.1B
-163%
2022
$5.0B
-63%
2021
$13.6B
+572%
2020
$2.0B
+542%
2019
-$459M
-39%
2018
-$331M
+0%
2017
-$331M
-597%
2016
$67M
Recent Quarterly Operating Cash Flow
Quarter
Operating Cash Flow
Q2 2026
-$526M
Q1 2026
-$630M
Q4 2025
$930M
Q3 2025
-$847M
Q2 2025
-$919M
Q1 2025
-$1.0B
Q4 2024
$825M
Q3 2024
-$1.6B
Q2 2024
-$1.3B
Q1 2024
-$989M
Q4 2023
$622M
Q3 2023
-$1.6B
Source: MRNA on EDGAR. Data from SEC EDGAR 10-K and 10-Q filings. Updated quarterly.